The company recalls products due to sterility concerns.
FDA announced on May 17, 2016 that Well Care Compounding Pharmacy (Las Vegas, NV) is voluntarily recalling sterile compounded products distributed between Jan. 1–April 29, 2016. The recall comes after an FDA inspection of the facility that resulted in sterility assurance concerns.
The company states in a press release that it has not received any adverse events related to the products, as of May 17. However, because administration of a sterile product that may be compromised could result in serious infections or death, the company is advising customers to stop using the recalled products.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.